Siegfried starts to ramp up production after cyber attack
Hameln plant which provides fill and finish for Pfizer-BioNTech COVID-19 shot should be fully operational within the week, CDMO says
Siegfried Group says it has started to ramp up production at its facilities after falling victim to a cyber-attack last month, although the Swiss-based CDMO warned of first-half losses in volumes and sales due to the interruption.
Siegfried said its plant in Hameln, Germany, which currently provides fill and finish services for BioNTech and Pfizer’s COVID-19 vaccine, should be fully operational again by the beginning of next week.
On the night of Friday, May 21, a malware attack on Siegfried's IT network was discovered by internal monitoring services which resulted in production being safely reduced at various locations.
The company’s network connections were interrupted and all IT systems were subsequently subjected to an in-depth investigation.
“As a result of the attack, there will be losses in volume and sales in the first half of the year with costs that continue to run during the brief interruption, but these can be made up for the whole year,” the company said in a statement.
Based on the results of advanced forensic investigations, no sensitive customer data was affected by the incident and there is no likely permanent damage to its IT infrastructure, systems and facilities, Siegfried said.
The CDMO’s two facilities in the Barcelona region of Spain, Barberà del Vallès and El Masno – which it acquired from Novartis last year -- were not affected by the incident as they run on isolated IT networks, Siegfried said.
Siegfried has facilities in Switzerland, Germany, Spain, France, Malta, the US and China and manufactures active pharmaceutical ingredients, intermediates and finished dosage forms such as tablets, capsules, sterile vials, ampoules, cartridges and ointments.
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance